ClinicalTrials.gg
CompletedNCT07107672Updated Aug 6, 2025

Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects

A Phase 1 interventional study of [14C]X842 in Gastroesophageal Reflux Disease, sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Jiangsu Sinorda Biomedicine Co., Ltd · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jun 2022, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Gastroesophageal Reflux with a site in China — 15 open to participants now, 16 under way, none of them phase 3. Gastroesophageal Reflux · China.

Enrollment
37th of 38
6 · median 89
Started
2022
with 5 others
Phase 1
2 of 55
none open now
Registered
45th of 55
by date
Lead sponsor
3 of 55
Jiangsu Sinorda Biomedicine Co., Ltd

Among the 55 studies in Gastroesophageal Reflux with a site in China, this one is the 37th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2022, is one of 2 in phase 1, and was the 45th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

15 of the 55 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Gastroesophageal Reflux with a site in China, or all of them as a file.
02

Study summary

This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects in China to ensure at least 4 evaluable subjects.

Read the detailed description

The healthy male subjects will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical research center 2 days before the dose (D-2). The subjects will receive a single oral administration of approximately 50 mg/100 µCi [14C]X842 suspension orally on an empty stomach on day 1.

Urine and feces samples will be all collected from the subjects before and at specified intervals between 0 and 312 hours after taking the drug and blood samples will be collected at specified time points between 0 and 216 hours before and after taking the drug.

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • Reflux Esophagitis
  • X842
  • Pharmacokinetics, PK
  • [14C]X842
  • linaprazan
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males;
  2. Age: 18 to 45 years (inclusive)
  3. Body weight: ≥50 kg with (BMI) between 19.0 and 26.0 kg/m² (inclusive);
  4. Fully understand the trial objectives, requirements, procedures, and potential adverse reactions; voluntarily participate; able to complete the study per protocol and comply with regulations; obtained in compliance with GCP;
  5. The subjects were able to communicate well with the researchers and complete the trial in accordance with the provisions of the protocol.

Exclusion criteria

Exclusion Criteria:

- Auxiliary Examinations:

  1. Subjects with abnormal and findings in Physical examination, Vital signs, Laboratory tests (including hematology, blood biochemistry, coagulation, urinalysis, fecal occult blood),Thyroid function, 12-lead , Anteroposterior chest X-ray, Abdominal ultrasound, and/or other clinically relevant investigations;
  2. Subjects testing positive for: surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab),Treponema pallidum antibody (syphilis screening);

    -Medication History:

  3. Subjects with use of any medications known to inhibit or induce hepatic drug-metabolizing enzymes within 30 days prior to screening;
  4. Subjects with use of any prescription medications, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (e.g., vitamins, calcium) within 14 days prior to screening;

    -Disease and Surgical History

  5. History of any clinically significant disease or condition that the investigator deems may affect the trial results, including but not limited to diseases of the circulatory, respiratory, endocrine, nervous, digestive, urinary systems, or blood, immune, psychiatric, and metabolic disorders;
  6. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsade de pointes, ventricular tachycardia, atrioventricular block, long syndrome, or family history thereof (as evidenced by genetic confirmation or sudden cardiac death of close relatives at a young age);
  7. Major surgery within 6 months prior to screening, or incompletely healed surgical wounds; Major surgery includes, but is not limited to, any procedure with significant bleeding risk, prolonged general anesthesia, open , or significant traumatic injury;
  8. Subjects have prone to allergies, such as a known history of to two or more substances; or individuals deemed by the investigator as potentially allergic to the trial drug or its ;
  9. Subjects with regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease;

    -life style

  10. Subjects with habitual constipation or diarrhea;
  11. Subjects who has the history of alcoholism or regular alcohol consumption within 6 months prior to screening, defined as consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), and inability to abstain during the trial period; or a breath alcohol test result ≥ 0 mg/dL at screening;
  12. Subjects who have smoked more than 5 cigarettes per day or habitually using nicotine-containing products within 3 months prior to screening, or who are unable to stop using any tobacco products during the trial;
  13. Subjects who have a history of drug abuse within three months prior to the screening period or whose urine test for prohibited drugs (morphine, methamphetamine, ketamine, dimethylene dioxyethanol, tetrahydrocannabinic acid) is positive during the screening;
  14. Subjects who has habitually consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages and are unable to quit during the trial period;
  15. Subjects who are exposed to radioactive work conditions for a long time, or have significant radiation exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-ray examinations) within 1 year before the first dose, or have participated in a radiopharmaceutical labeled trial;
  16. Subjects with a history of blood or needle phobia, and those who have difficulty in blood collection or cannot tolerate venipuncture blood collection;
  17. Subjects have participated in any other clinical trial (including trials of drugs or medical devices, etc.) within 3 months prior to the screening period.
  18. Subjects who have received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
  19. subjects who plan to conceive or donate sperm during the trial period or within 1 year after trial completion, or those who do not agree that the subject and their partner must use highly effective during the trial period and for 1 year after trial completion;
  20. Subjects who have lost blood or donated blood (200mL), or received blood transfusions within 3 month before the screening period.
  21. Subjects who are unsuitable for the study participation for other reasons at the discretion of the investigator;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]X842 suspension approximately 50 mg/ 100 µCi[14C]X842

    a single oral administration of approximately 50 mg/ 100 µCi \[14C\]X842 suspension orally on an empty stomach on day 1

    Drug: [14C]X842

Interventions

  • 50 mg/100 µCi \[14C\] X842 suspension

    Also known as: [14C]X842 suspension

06

What researchers measure

Primary outcomes

  1. Mass balance: the cumulative excretion rate

    To collect the total radioactive substances in excreta (urine and feces) and to calculate the cumulative excretion rate

    Time frame: 22 days

  2. Tmax (time to maximum observed concentration)

    Tmax parameters of the total radioactivity in plasma

    Time frame: 22 days

  3. Cmax(maximum concentration)

    Cmax parameters of the total radioactivity in plasma

    Time frame: 22 days

  4. AUC(area under curve)

    AUC parameters of the total radioactivity in plasma

    Time frame: 22 days

  5. t1/2 (terminal elimination half-life)

    t1/2 parameters of the total radioactivity in plasma

    Time frame: 22 days

  6. MRT (mean residence time)

    MRT parameters of the total radioactivity in plasma

    Time frame: 22 days

  7. Vd/F(apparent volume of distribution)

    Vd/F parameters of the total radioactivity in plasma

    Time frame: 22 days

  8. whole blood/plasma ratio for the total radioactivity concentration at different time points

    whole blood/plasma ratio for the total radioactivity concentration at different time points

    Time frame: 22 days

  9. Percentage of the drug and its metabolites in plasma, urine and feces to the administered dose

    Exposure in plasma; percentage of the drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces

    Time frame: 22 days

Secondary outcomes

  1. The nature and severity of AEs based on NCI-CTC AE V5.0

    The nature and severity of adverse events were adjudicated in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)

    Time frame: 22 days

  2. The nature and incidence and severity of SAEs based on NCI-CTC AE V5.0

    The nature and severity of serious adverse events were adjudicated in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)

    Time frame: 22 days

  3. 12-Electrocardiograms (ECG)

    the data collection of heart rate, PR interval, QRS interval, QT, QTc, on D-1 and 2 hours (±30 min) after administration

    Time frame: 22 days

  4. vital signs of pulse

    pulse (beats per minute)

    Time frame: 22 days

  5. vital signs of body temperature

    body temperature (℃)

    Time frame: 22 days

  6. vital signs of blood pressure

    measurements included systolic (mmHg) and diastolic (mmHg).

    Time frame: 22 days

  7. vital signs of respiratory rate

    respiratory rate (breaths per minute).

    Time frame: 22 days

  8. Hematology - Number of participants with clinically significant abnormalities

    including White blood cell count, lymphocyte count, neutrophil count, red blood cell count, hemoglobin, platelet count

    Time frame: 22 days

  9. Blood Chemistry - Number of participants with clinically significant abnormalities

    Blood Biochemistry including: Total Bilirubin (TBIL), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-Glutamyl Transferase (GGT), Alkaline Phosphatase (ALP), Total Protein (TP), Albumin (ALB), Urea, Creatinine (Cr), Uric Acid (UA), Glucose (GLU), Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Low-Density Lipoprotein Cholesterol (LDL-C), Triglycerides (TG), Potassium (K+), Sodium (Na+), Chloride (Cl-), Lactate Dehydrogenase (LDH), Creatine Kinase (CK), Amylase (AMY).

    Time frame: 22 days

  10. Coagulation - Number of participants with clinically significant abnormalities

    including Prothrombin Time (PT), Thrombin Time (TT), Activated Partial ,, hromboplastin Time (APTT/aPTT),Fibrinogen (FIB/Fg), International Normalized Ratio (INR)

    Time frame: 22 days

  11. Urinalysis - Number of participants with clinically significant abnormalities

    Urinalysis including Urinary protein, urine sugar, urine ketone bodies, red blood cells, white blood cells, pH value

    Time frame: 22 days

  12. Fecal Occult Blood Test (FOBT) - Number of participants with positive result

    Fecal Occult Blood Test (FOBT) result

    Time frame: 22 days

07

Study locations

1 site
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233099, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jul 2022, 0 months.

Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 0 months is below that.

Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Aug 6, 2025
StartActual
Jun 15, 2022
Primary completionActual
Jul 7, 2022
CompletionActual
Nov 14, 2022
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07107672
Lead sponsor
Jiangsu Sinorda Biomedicine Co., Ltd
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Jun 15, 2022
Primary completion
Jul 7, 2022
Completion
Nov 14, 2022
Last update
Aug 6, 2025

Study contacts

Huan Zhou
principal investigator · The First Affiliated Hospital of Bengbu Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linaprazan glurate

Start the discussion